Insider Transactions in Q3 2021 at Cullinan Oncology, Inc. (CGEM)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 20
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
7,468
-11.42%
|
$186,700
$25.16 P/Share
|
|
Sep 20
2021
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.63%
|
$96,000
$24.77 P/Share
|
|
Sep 20
2021
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+12.94%
|
$16,000
$4.3 P/Share
|
|
Sep 16
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
3,124
-0.04%
|
$90,596
$29.06 P/Share
|
|
Sep 16
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
432
-0.18%
|
$12,528
$29.06 P/Share
|
|
Sep 16
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,124
-0.04%
|
$90,596
$29.06 P/Share
|
|
Sep 15
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
6,425
-0.08%
|
$186,325
$29.16 P/Share
|
|
Sep 15
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
888
-0.36%
|
$25,752
$29.16 P/Share
|
|
Sep 15
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,425
-0.08%
|
$186,325
$29.16 P/Share
|
|
Sep 14
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
7,106
-0.09%
|
$206,074
$29.17 P/Share
|
|
Sep 14
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
982
-0.4%
|
$28,478
$29.17 P/Share
|
|
Sep 14
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
7,106
-0.09%
|
$206,074
$29.17 P/Share
|
|
Sep 13
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
3,595
-0.05%
|
$104,255
$29.1 P/Share
|
|
Sep 13
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
497
-0.2%
|
$14,413
$29.1 P/Share
|
|
Sep 13
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,595
-0.05%
|
$104,255
$29.1 P/Share
|
|
Sep 10
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
5,931
-0.08%
|
$171,999
$29.04 P/Share
|
|
Sep 10
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
820
-0.33%
|
$23,780
$29.04 P/Share
|
|
Sep 10
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,931
-0.08%
|
$171,999
$29.04 P/Share
|
|
Sep 09
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
13,727
-0.18%
|
$398,083
$29.35 P/Share
|
|
Sep 09
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,898
-0.76%
|
$55,042
$29.35 P/Share
|
|
Sep 09
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,727
-0.18%
|
$398,083
$29.35 P/Share
|
|
Sep 08
2021
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-56.34%
|
$420,000
$28.34 P/Share
|
|
Sep 08
2021
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+46.51%
|
$60,000
$4.3 P/Share
|
|
Sep 08
2021
|
Patrick Baeuerle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,000
-100.0%
|
$308,000
$28.45 P/Share
|
|
Sep 08
2021
|
Patrick Baeuerle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+50.0%
|
$44,000
$4.3 P/Share
|
|
Sep 08
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
10,842
-0.14%
|
$314,418
$29.11 P/Share
|
|
Sep 08
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,499
-0.6%
|
$43,471
$29.11 P/Share
|
|
Sep 08
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
10,842
-0.14%
|
$314,418
$29.11 P/Share
|
|
Sep 07
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
28,118
-30.07%
|
$787,304
$28.95 P/Share
|
|
Sep 07
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
25,067
-0.32%
|
$726,943
$29.04 P/Share
|
|
Sep 07
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
3,465
-1.36%
|
$100,485
$29.04 P/Share
|
|
Sep 07
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
25,067
-0.32%
|
$726,943
$29.04 P/Share
|
|
Sep 03
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
12,731
-0.16%
|
$369,199
$29.6 P/Share
|
|
Sep 03
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,760
-0.69%
|
$51,040
$29.6 P/Share
|
|
Sep 03
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
12,731
-0.16%
|
$369,199
$29.6 P/Share
|
|
Sep 02
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
15,757
-0.2%
|
$456,953
$29.46 P/Share
|
|
Sep 02
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
2,178
-0.84%
|
$63,162
$29.46 P/Share
|
|
Sep 02
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
15,757
-0.2%
|
$456,953
$29.46 P/Share
|
|
Sep 01
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
5,714
-0.07%
|
$165,706
$29.47 P/Share
|
|
Sep 01
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
790
-0.3%
|
$22,910
$29.47 P/Share
|
|
Sep 01
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,714
-0.07%
|
$165,706
$29.47 P/Share
|
|
Aug 31
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
2,838
-0.02%
|
$82,302
$29.79 P/Share
|
|
Aug 31
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
392
-0.08%
|
$11,368
$29.79 P/Share
|
|
Aug 31
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,838
-0.02%
|
$82,302
$29.79 P/Share
|
|
Aug 30
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
31,001
-0.4%
|
$899,029
$29.3 P/Share
|
|
Aug 30
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
4,285
-1.62%
|
$124,265
$29.3 P/Share
|
|
Aug 30
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
31,001
-0.4%
|
$899,029
$29.3 P/Share
|
|
Aug 27
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
13,357
-0.17%
|
$387,353
$29.09 P/Share
|
|
Aug 27
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,846
-0.69%
|
$53,534
$29.09 P/Share
|
|
Aug 27
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,357
-0.17%
|
$387,353
$29.09 P/Share
|